The mRNA vaccine BNT162b2 demonstrates impaired T(H)1 immunogenicity in human elders in vitro and aged mice in vivo

mRNA vaccines have been key to addressing the SARS-CoV-2 pandemic but have impaired immunogenicity and durability in vulnerable older populations. We evaluated the mRNA vaccine BNT162b2 in human in vitro whole blood assays with supernatants from adult (18–50 years) and elder (≥60 years) participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Brook, Byron, Fatou, Benoit, Kumar Checkervarty, Abhinav, Barman, Soumik, Sweitzer, Cali, Bosco, Anna-Nicole, Sherman, Amy C., Baden, Lindsey R., Morrocchi, Elena, Sanchez-Schmitz, Guzman, Palma, Paolo, Nanishi, Etsuro, O’Meara, Timothy R., McGrath, Marisa E., Frieman, Matthew B., Soni, Dheeraj, van Haren, Simon D., Ozonoff, Al, Diray-Arce, Joann, Steen, Hanno, Dowling, David J., Levy, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810224/
https://www.ncbi.nlm.nih.gov/pubmed/36597547
http://dx.doi.org/10.21203/rs.3.rs-2395118/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810224/
https://www.ncbi.nlm.nih.gov/pubmed/36597547
http://dx.doi.org/10.21203/rs.3.rs-2395118/v1

Ejemplares similares